JP2010509379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509379A5 JP2010509379A5 JP2009536625A JP2009536625A JP2010509379A5 JP 2010509379 A5 JP2010509379 A5 JP 2010509379A5 JP 2009536625 A JP2009536625 A JP 2009536625A JP 2009536625 A JP2009536625 A JP 2009536625A JP 2010509379 A5 JP2010509379 A5 JP 2010509379A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- formula
- conh
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- LFVRANFPFBGCPD-CFDCCIPKSA-N CCCC[C@](CC)(CS(c(cc1)c([C@H]2c3cccc(NC(N[C@@H]([C@@H]4O)O[C@H](COS(O)(O)=O)[C@@H](C)[C@@H]4OCc4ccccc4)=O)c3)cc1N(C)C)(=O)=O)[C@@H]2O Chemical compound CCCC[C@](CC)(CS(c(cc1)c([C@H]2c3cccc(NC(N[C@@H]([C@@H]4O)O[C@H](COS(O)(O)=O)[C@@H](C)[C@@H]4OCc4ccccc4)=O)c3)cc1N(C)C)(=O)=O)[C@@H]2O LFVRANFPFBGCPD-CFDCCIPKSA-N 0.000 description 2
- 0 CCCCC(*)(CS(c(c([C@]1c2cccc(NC(*C3OC(*)(*)C(C)(C)C(C)(C)C3=*)=O)c2)c2)ccc2N(C)C)(=O)=O)C1O Chemical compound CCCCC(*)(CS(c(c([C@]1c2cccc(NC(*C3OC(*)(*)C(C)(C)C(C)(C)C3=*)=O)c2)c2)ccc2N(C)C)(=O)=O)C1O 0.000 description 1
- RPZKKZRKMDBVND-FSPHGCPUSA-N CCCCC(CCCC)(CS(c(c([C@H]1c2cc(NC(NC([C@@H]([C@H]3OCc4ccccc4)O)O[C@H](COS(O)(=O)=O)[C@H]3O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O Chemical compound CCCCC(CCCC)(CS(c(c([C@H]1c2cc(NC(NC([C@@H]([C@H]3OCc4ccccc4)O)O[C@H](COS(O)(=O)=O)[C@H]3O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O RPZKKZRKMDBVND-FSPHGCPUSA-N 0.000 description 1
- ACGFUAUGMVHLCR-RTNCXNSASA-N CCCC[C@](CC)(CS(c(c([C@H]1c2cc(NC(N[C@@H]([C@@H]([C@H]3OCc4ccccc4)O)O[C@H](COS(O)(O)O)[C@H]3O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O Chemical compound CCCC[C@](CC)(CS(c(c([C@H]1c2cc(NC(N[C@@H]([C@@H]([C@H]3OCc4ccccc4)O)O[C@H](COS(O)(O)O)[C@H]3O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O ACGFUAUGMVHLCR-RTNCXNSASA-N 0.000 description 1
- MKEUYRSOYYXUAR-UUZXJHQBSA-N CCCC[C@](CC)(CS(c(cc1)c([C@H]2c3cccc(NC(N[C@@H]([C@@H](C4OCc5ccccc5)O)O[C@H](COS(O)(O)=O)[C@H]4O)=O)c3)cc1N(C)C)(=O)=O)[C@@H]2O Chemical compound CCCC[C@](CC)(CS(c(cc1)c([C@H]2c3cccc(NC(N[C@@H]([C@@H](C4OCc5ccccc5)O)O[C@H](COS(O)(O)=O)[C@H]4O)=O)c3)cc1N(C)C)(=O)=O)[C@@H]2O MKEUYRSOYYXUAR-UUZXJHQBSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006053635A DE102006053635B4 (de) | 2006-11-14 | 2006-11-14 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE102006053635.5 | 2006-11-14 | ||
| PCT/EP2007/009393 WO2008058628A1 (de) | 2006-11-14 | 2007-10-30 | Neue mit benzylresten substituierte 1,4-benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509379A JP2010509379A (ja) | 2010-03-25 |
| JP2010509379A5 true JP2010509379A5 (enExample) | 2010-12-02 |
| JP5301453B2 JP5301453B2 (ja) | 2013-09-25 |
Family
ID=39092812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536625A Active JP5301453B2 (ja) | 2006-11-14 | 2007-10-30 | ベンジル基によって置換された新規な１，４−ベンゾチエピン１，１−ジオキシド誘導体、その製造方法、その化合物を含む医薬及びその使用 |
Country Status (37)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8461312B2 (en) * | 2008-05-02 | 2013-06-11 | Sanofi | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives |
| EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| EP4137137A1 (en) * | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| CN103298469A (zh) | 2010-08-31 | 2013-09-11 | 首尔大学校产学协力财团 | PPARδ激动剂的胎儿重编程的用途 |
| MX366925B (es) | 2010-11-04 | 2019-07-31 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepaticas. |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EA038594B1 (ru) * | 2011-10-28 | 2021-09-21 | Шайр Хьюман Дженетик Терапис, Инк. | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени |
| JP6217938B2 (ja) * | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| JP6954927B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
| CN108601744B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| CA3011595C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| JP7391048B2 (ja) | 2018-06-05 | 2023-12-04 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| KR20210024033A (ko) | 2018-06-20 | 2021-03-04 | 알비레오 에이비 | 오데빅시바트의 약학 제제 |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| EP3841123A2 (en) | 2018-08-23 | 2021-06-30 | Seagen Inc. | Anti-tigit antibodies |
| SG11202108566VA (en) | 2019-02-06 | 2021-09-29 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN113453753B (zh) | 2019-02-06 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| EP4424363B1 (en) | 2019-02-12 | 2026-04-29 | Mirum Pharmaceuticals, Inc. | Methods for increasing growth in pediatric subjects having cholestatic liver disease |
| JP7665621B2 (ja) | 2019-12-04 | 2025-04-21 | アルビレオ・アクチボラグ | ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3158195A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2021110885A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| ES3002777T3 (en) | 2020-08-03 | 2025-03-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| CN117412955A (zh) | 2021-06-03 | 2024-01-16 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CN119053330A (zh) | 2022-04-22 | 2024-11-29 | 阿尔比里奥公司 | 皮下给药asbt抑制剂 |
| EP4536232A1 (en) | 2022-06-09 | 2025-04-16 | Albireo AB | Treating hepatitis |
| EP4629997A1 (en) | 2022-12-09 | 2025-10-15 | Albireo AB | Asbt inhibitors in the treatment of renal diseases |
| AU2024276707A1 (en) * | 2023-05-19 | 2025-10-23 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising 2,3,4,5-tetrahydro-benzothiepin-1,1-dioxide derivatives and the use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| WO2003018024A1 (de) * | 2001-08-22 | 2003-03-06 | Aventis Pharma Deutschland Gmbh | Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung |
| GB0121621D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| BR0213501A (pt) | 2001-11-02 | 2004-08-24 | Searle Llc | Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
-
2006
- 2006-11-14 DE DE102006053635A patent/DE102006053635B4/de not_active Expired - Fee Related
-
2007
- 2007-10-30 MX MX2009003958A patent/MX2009003958A/es active IP Right Grant
- 2007-10-30 AT AT07819434T patent/ATE492554T1/de active
- 2007-10-30 DE DE502007006055T patent/DE502007006055D1/de active Active
- 2007-10-30 MY MYPI20091688A patent/MY148429A/en unknown
- 2007-10-30 EP EP07819434A patent/EP2084172B1/de active Active
- 2007-10-30 DK DK07819434.7T patent/DK2084172T3/da active
- 2007-10-30 NO NO20091893A patent/NO342236B1/no unknown
- 2007-10-30 CA CA2669230A patent/CA2669230C/en active Active
- 2007-10-30 CA CA2865332A patent/CA2865332C/en active Active
- 2007-10-30 PL PL07819434T patent/PL2084172T3/pl unknown
- 2007-10-30 BR BRPI0718813A patent/BRPI0718813B8/pt active IP Right Grant
- 2007-10-30 SI SI200730487T patent/SI2084172T1/sl unknown
- 2007-10-30 NZ NZ576762A patent/NZ576762A/en unknown
- 2007-10-30 PT PT07819434T patent/PT2084172E/pt unknown
- 2007-10-30 KR KR1020097009914A patent/KR101489168B1/ko active Active
- 2007-10-30 WO PCT/EP2007/009393 patent/WO2008058628A1/de not_active Ceased
- 2007-10-30 CN CN2007800424399A patent/CN101535326B/zh active Active
- 2007-10-30 AU AU2007321496A patent/AU2007321496B2/en active Active
- 2007-10-30 JP JP2009536625A patent/JP5301453B2/ja active Active
- 2007-10-30 ES ES07819434T patent/ES2358371T3/es active Active
- 2007-10-30 HR HR20110197T patent/HRP20110197T1/hr unknown
- 2007-10-30 RU RU2009122470/04A patent/RU2456282C2/ru active
- 2007-11-12 AR ARP070105027A patent/AR063786A1/es active IP Right Grant
- 2007-11-12 PE PE2007001553A patent/PE20081493A1/es not_active Application Discontinuation
- 2007-11-12 TW TW096142599A patent/TWI414530B/zh active
- 2007-11-12 UY UY30709A patent/UY30709A1/es unknown
- 2007-11-13 CL CL200703262A patent/CL2007003262A1/es unknown
-
2009
- 2009-04-03 SV SV2009003216A patent/SV2009003216A/es unknown
- 2009-04-20 CR CR10733A patent/CR10733A/es not_active Application Discontinuation
- 2009-05-04 NI NI200900076A patent/NI200900076A/es unknown
- 2009-05-06 CO CO09045559A patent/CO6190534A2/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000180A patent/TN2009000180A1/fr unknown
- 2009-05-12 IL IL198718A patent/IL198718A/en active IP Right Grant
- 2009-05-12 MA MA31864A patent/MA30883B1/fr unknown
- 2009-05-13 GT GT200900125A patent/GT200900125A/es unknown
- 2009-05-13 EC EC2009009327A patent/ECSP099327A/es unknown
- 2009-05-14 US US12/465,911 patent/US7956085B2/en active Active
-
2011
- 2011-02-04 CY CY20111100133T patent/CY1111166T1/el unknown
-
2017
- 2017-07-12 AR ARP170101938A patent/AR109033A2/es unknown
-
2018
- 2018-04-11 NO NO20180497A patent/NO344589B1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539268A5 (enExample) | ||
| JP2007534702A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| JP2010536766A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2010526025A5 (enExample) | ||
| JP2011513196A5 (enExample) | ||
| JP2007277267A5 (enExample) | ||
| JP2006522035A5 (enExample) | ||
| JP2008535803A5 (enExample) | ||
| RU2008145971A (ru) | Производные 2-тиоксантина, действующие в качестве ингибиторов мро | |
| JP2010521514A5 (enExample) | ||
| NZ566788A (en) | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | |
| JP2011513410A5 (enExample) | ||
| JP2013509392A5 (enExample) | ||
| JP2007231005A5 (enExample) | ||
| JP2009538276A5 (enExample) | ||
| MY148988A (en) | Terphenyl derivatives for treatment of alzheimer's disease | |
| MX2010005283A (es) | Compuestos de piridilmetil-sulfonamida. | |
| JP2007532627A5 (enExample) | ||
| EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
| JP2006504738A5 (enExample) | ||
| JP2008520662A5 (enExample) | ||
| JP2011526252A5 (enExample) | ||
| JP2011528662A5 (enExample) |